SCHEMBL589337

SCHEMBL589337

NC(=O)c1cccc(S(=O)(=O)c2ccccc2)c1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
NPY1R P25929 1/20 0.43
MMP2 P08253 3/20 0.43
MMP3 P08254 3/20 0.43
MMP9 P14780 3/20 0.43
MMP8 P22894 3/20 0.43
MMP12 P39900 3/20 0.43
MMP13 P45452 3/20 0.43
MMP14 P50281 3/20 0.43
MMP16 P51512 3/20 0.43
MMP1 P03956 2/20 0.43
KIF18A Q8NI77 1/20 0.43
HTR6 P50406 1/20 0.42
ALDH1A1 P00352 3/20 0.42
GAA P10253 1/20 0.42
POLB P06746 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
MEN1 O00255 3/20 0.40
IKBKB O14920 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3069224 0.82 ALDH1A1 (0.40) KMT2AALDH1A1GAAPOLBMEN1
SCHEMBL1831961 0.81 TDP1 (0.40) KMT2AALDH1A1GAAPOLBMEN1
SCHEMBL364480 0.80 HTR6 (0.55) KMT2AMMP2MMP3MMP9MMP8
SCHEMBL11591250 0.79 HTR6 (0.61) KMT2ANPY1RKIF18AHTR6GAA
SCHEMBL2903876 0.79 KMT2A (0.58) KMT2ANPY1RKIF18AHTR6ALDH1A1
SCHEMBL31347931 0.78 ALDH1A1 (0.39) KMT2AALDH1A1GAAPOLBMEN1
SCHEMBL30364159 0.78 KMT2A (0.60) KMT2AMMP2MMP9MMP8MMP13
SCHEMBL5792626 0.78 TSHR (0.48) KMT2AALDH1A1GAAPOLBMEN1
SCHEMBL589633 0.77 HTR6 (0.53) MMP2MMP3MMP9MMP8MMP12
SCHEMBL2230607 0.77 KMT2A (0.75) KMT2ANPY1RMMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101594862-B Substituted indazole derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-11-25 CN disclosed
EP-2120932-B1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2014-07-09 EP disclosed
US-8114865-B2 Indazole derivatives as kinase inhibitors for the treatment of cancer NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-14 US disclosed
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-08-05 US disclosed
EP-2120932-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Nerviano Medical Sciences S.r.l. (IT) 2009-11-25 EP disclosed
WO-2008074749-A9 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2009-05-07 WO disclosed
WO-2008074749-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER MAP3K5, MAP3K19, MAP3K3 KMT2A 1074/4885NPY1R 4488/4885MMP2 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.